


Amendments to the Claims

1. (Currently amended) A method of treating an infection caused by herpesviridae or poxyviridae in a mammalian subject in need thereof comprising administering to said subject an effective amount of at least one compound according to the formula



wherein R₁ is selected from the group consisting of alkyl, aryl, O-aryl, S-aryl, OH, O-alkyl, SH, S-alkyl, NH₂, N₃, halogens, -OOCH, and COOH;

wherein R₂ is selected from the group consisting of H, hydroxyl, aliphatic and aromatic ethers and esters;

wherein R₃ is selected from the group consisting of alkyl, aryl, O-aryl, S-aryl, OH, O-alkyl, SH, S-alkyl, NH₂, N₃, halogens, -OOCH, COOH, siloxane rings, and acetal rings; and

wherein R₄ is selected from the group consisting of alkyl, aryl, O-aryl, S-aryl, OH, O-alkyl, SH, S-alkyl, NH₂, N₃, halogens, -OOCH, COOH, siloxane rings, and acetal rings; and

~~wherein X is selected from the group consisting of O, NH and S.~~

2. (Previously amended) A method as defined in claim 1, wherein R₁ is phenyl; R₂ is selected from the group consisting of -OMe, -OH, and -H; R₃ is selected from the group consisting of -OH, -OAc, -OH, and -OBn; and R₄ is selected from the group consisting of -H, -OAc, and -OBn; or a pharmaceutically active derivative thereof.

3. (Previously amended) A method as defined in claim 1, wherein R₁ and R₂ form a ring comprising -OC(CH₃)₂O-.

4. (Previously amended) A method as defined in claim 1, wherein R₃ and R₄ form a ring comprising a moiety preferably selected from the group consisting of -OSi(*i*-Pr)₂OSi(*i*-Pr)₂O- and -OCH(Ph)O-.
5. (Canceled)
6. (Canceled)
7. (Canceled)
8. (Previously amended) A method as defined in claim 1, wherein the infection is an infection caused by Cytomegalovirus.
9. (Previously added) A method according to claim 1, wherein the infection is an infection caused by Vaccinia virus.
10. (Previously added) A method according to claim 1, further comprising wherein R₃ and R₄ comprise -OAc.
11. (Canceled)
12. (Canceled)